Research and development expenses decreased primarily due to a decrease in expense related to our SMARCA2 clinical trials which we paused in 2025 along with a decrease in employee related expenses due to the workforce reduction in the second half of 2025.

filing / Aug 11, 2026 / receipt

Workforce Reduction During 2025, the Company reduced its workforce by approximately 27 % of full-time employees to align its resources with its ongo ing clinical and preclinical programs.

filing / Aug 11, 2026 / receipt

Workforce Reduction During 2025, the Company reduced its workforce by approximately 27 % of full-time employees to align its resources with its ongo ing clinical and preclinical programs.

filing / May 12, 2026 / receipt

Workforce reduction $ 711 $ - $ ( 694 ) $ - $ 17 13. Subsequent Events In April 2026, the Company sold an aggregate of (a) 16,611,014 shares of its voting common stock, par value $ 0.0001 per share (the “Common Stock”), at a price of $ 4.44 per share, and (b) pre-funded warrants to purchase up to 3,659,252 shares of its Common Stock (the “Pre-Funded Warrants”), at a price of $ 4.4399 per war

filing / May 12, 2026 / receipt